Research
Hormonal
Exposure to environmental endocrine-disrupting chemicals (EDCs) is associated with adverse reproductive health outcomes in both males and females, including reduced fertility, altered puberty timing, and increased risk of conditions like PCOS and endometriosis.
Minimize exposure to EDCs by avoiding plastic food containers, especially when heating food, and choosing personal care products free of phthalates and parabens. This is particularly important for those planning pregnancy or currently pregnant.
ModerateSupportsMEDIUM confidence
EDCs are associated with deleterious effects on male and female reproductive health... Several EDCs are known to exert effects on female reproductive hormones... EDCs are thought to affect the menstrual cycle, alter fertility and oogenesis and are implicated in diseases such as polycystic ovary syndrome (PCOS) and endometriosis.
Why this rating
The paper reviews multiple studies with variable results, noting that exact mechanisms are not always clear and some studies show no association.
Source
Environmental Endocrine-Disrupting Chemical Exposure: Role in Non-Communicable Diseases
Manoj Kumar et al. · Frontiers in Public Health · 2020
DOI 10.3389/fpubh.2020.553850
narrative_reviewCited 374×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Exposure to environmental endocrine-disrupting chemicals (EDCs) such as BPA, phthalates, and persistent organic pollutants acts as an obesogen, contributing to obesity, metabolic syndrome, and type 2 diabetes by disrupting endocrine pathways, adipogenesis, and gut microbiota.Moderate
- Exposure to environmental endocrine-disrupting chemicals (EDCs) is associated with adverse neurodevelopmental outcomes in children, including lower IQ, attention deficit, hyperactivity, and behavioral problems.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →